REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10 billion in funding
May 13, 2021
Share
REYON Pharmaceutical Co., Ltd. announced a private placement of 500,000 convertible preferred shares at a price of KRW 20,000 per share for gross proceeds of KRW on May 14, 2021. The transaction will include participation from funds managed by Samsung Securities Co., Ltd. The transaction will be raised through a third party allocation increase. The conversion period will start from July 25, 2026 to July 26, 2026. The shares are convertible into 500,000 common shares of the company. The payment date is July 26, 2021. The transaction has been approved by the board of the company.
On July 19, 2021, the company announced that the conversion period will start from July 26, 2026 to July 27, 2026. Samsung Securities Co., Ltd. is longer investing in the transaction.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
